
1,2-Dihydro-5-nitro-3H-1,2,4-triazol-3-one | CAS:932-64-9
1,2-Dihydro-5-nitro-3H-1,2,4-triazol-3-one
- 名称:1,2-二氢-5-硝基-3H-1,2,4-三唑-3-酮 | 1,2-Dihydro-5-nitro-3H-1,2,4-triazol-3-one
- CAS号:932-64-9
- 别名:3-Nitro-1,2,4-triazol-5-one; 3-Nitro-1,2,4-triazole-5-one; 5-Nitro-2,4-dihydro-1,2,4-triazol-3-one; 5-Nitro-2,4-dihydro-3H-1,2,4-triazol-3-one; 5-Oxo-3-nitro-1,2,4-triazole; NSC 119860; NTO; NTO (explosive)
- 分子式:C2H2N4O3
- 分子量:130.06
- EINESC号:213-254-4
产品描述
物理化学性质
熔点 | 270-271 ºC*** |
---|---|
密度 | 1.92 g/cm3** |
安全数据
没有数据 | 没有数据 |
---|
SDS
来源 | SDS样本 |
---|---|
没有数据 | 没有数据 |
产品合成路线
名称 | CAS号 |
---|
更多
文章
同行评议文献
Population screening for hemochromatosis: a study in 5370 Spanish blood donors.Mayka Sánchez et al.Journal of hepatology, 38(6), 745-750 (2003-05-24)
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.J M Hartikainen et al.Clinical genetics, 72(4), 311-320 (2007-09-14)
Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD.K Nakai et al.American journal of cardiovascular drugs : drugs, devices, and other interventions, 1(5), 353-361 (2004-01-20)
Human muscle economy myoblast differentiation and excitation-contraction coupling use the same molecular partners, STIM1 and STIM2.Basile Darbellay et al.The Journal of biological chemistry, 285(29), 22437-22447 (2010-05-04)
PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.De-Wei Wu et al.Clinical cancer research : an official journal of the American Association for Cancer Research, 22(21), 5370-5382 (2016-11-03)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
名称 | CAS号 |
---|

相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称!
- CAS号
- 请正确填写公司名称!
- 请正确填写联系人!
- 请正确填写联系电话!
- 请正确填写联系邮箱!
- 请描述您的问题!